RNA Formulation Videos

1. Hear From The Experts: LNPs Driving The Future Of Cell Therapy 12/12/2025

   Explore how lipid nanoparticles are driving breakthroughs in cell therapy, from mRNA-based immune cell engineering to genome editing for CAR T cells and HSPCs from leading experts.

2. An Early Formulation Screening Service 5/23/2024

   Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

3. DNA Vaccine Development In A Global Pandemic: A Personal Account 4/14/2022

   Dr. Gerrit Borchard, University of Geneva, presents a personal account of DNA vaccine development in a global pandemic.

4. What Does 2025 (And Beyond) Hold For The RNA-LNP Space? 12/4/2024

   Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.

5. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

   mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

6. In What Ways Are We Underestimating LNP Complexity Today? 12/4/2024

   As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.

7. Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines 4/13/2022

   Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.

8. How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing

   Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.

9. Complexity, Biodegradability, And Scale In Active LNP R&D 2/24/2026

   NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris walk us through the challenges active delivery strategies pose, particularly as it relates to receptor selection, and the emerging technologies/tools that can help us achieve greater delivery specificity to the target cell type.

10. Transforming Nanoparticles By Continuous Manufacturing 9/13/2025

    Discover how continuous manufacturing of nanoparticles can improve process efficiency, reduce costs, and increase the quality of the final drug product.